90
Participants
Start Date
November 14, 2023
Primary Completion Date
May 31, 2025
Study Completion Date
June 30, 2025
Intranasal Midazolam
Using a computer-generated randomization schedule by the research pharmacist, all 90 subjects will be divided into 3 even groups to receive either medication A (intranasal Midazolam), B (intranasal Dexmedetomidine), or C (intranasal Ketamine). Based on the randomization schedule, the pharmacist will dispense medication A, B, or C to the chronological number provided in the order. The total amount of the medication will be based on the patient's charted weight. Small volumes of less than 1ml per nostril are preferred for reliable absorption; therefore, the medication will be dispensed in a 1ml syringe and the barrel of the syringe will be covered by the pharmacist. All the syringes sent from the pharmacy will appear the same, regardless of the volume of the medication.
Intranasal Dexmedetomidine
See above
Intranasal Ketamine
See above
RECRUITING
University of Oklahoma Health Sciences Center, Oklahoma City
University of Oklahoma
OTHER